DSIP (Delta Sleep-Inducing Peptide)

DSIP is a tiny peptide (a short chain of amino acids, the building blocks of proteins) that was first pulled from rabbit brain blood in the 1970s. It got its name because it seemed to bring on deep (“delta”) sleep. Decades later, it’s sold all over the internet as a sleep aid — but the human research behind it is thin, old, and all over the map.

What it is

DSIP (delta sleep-inducing peptide) is a nine-amino-acid neuropeptide (a small signaling molecule made of amino acids that acts in the brain and nervous system). Its sequence is Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. Swiss researchers Schoenenberger and Monnier first isolated it in 1974, drawing it from the blood leaving the brains of rabbits that had been put into a sleep state. The body makes it naturally, and DSIP-like material has even been found in human breast milk — so it isn’t a lab-designed drug, but something our bodies already produce.

How it actually works is still poorly understood. It’s also very fragile inside the body: a specific enzyme (a protein that breaks other molecules apart) chews it up quickly. One lab-dish estimate put its half-life (the time it takes for half of it to disappear) at around 15 minutes. That short lifespan makes it hard to use as a medicine.

The claims

Sellers and peptide-forum posts mostly promote DSIP for better, deeper sleep and for easing insomnia (trouble falling or staying asleep). Other claims include less stress, dulled pain, easier withdrawal from opioids and alcohol, and feeling more recovered during the day. Some marketing pitches it as a “natural” sleep peptide that won’t leave you groggy the next morning. All of these claims run well ahead of what the published human studies actually back up.

What the evidence actually shows

The clinical record is small, and most of it comes from the 1980s. The biggest controlled study was a placebo-controlled, double-blind report by Schneider-Helmert (European Neurology, 1987). (Placebo-controlled means some people got a dummy treatment for comparison; double-blind means neither the patients nor the researchers knew who got which.) It gave DSIP to 14 middle-aged people with long-term insomnia over seven nights and found better nighttime sleep and more daytime alertness. An earlier double-blind report from the same group (Experientia, 1981) tested only 6 chronic insomniacs and described longer, less broken-up sleep with no daytime drowsiness. A separate open (unblinded — everyone knew they were getting DSIP) trial of 7 severe insomniacs (Kaeser, European Neurology, 1984) reported that sleep “normalized” in all but one patient for several months. Small reports also described symptom relief in people dependent on opioids and alcohol.

But here’s the other side. A 2006 review bluntly called DSIP’s status “a still unresolved riddle.” It judged the idea that DSIP works as a sleep factor “extremely poorly documented and still weak,” and pointed out that some close chemical relatives of DSIP — but not DSIP itself — showed activity in animals. The supportive trials are tiny (anywhere from single digits to the low teens of patients), decades old, sometimes unblinded, short, and never repeated by modern, properly sized studies. (An RCT, or randomized controlled trial, is the gold-standard study design that randomly assigns people to treatment or comparison groups.) Other studies found no sleep effect at all. That puts DSIP at the early, mixed end of the human-evidence scale — not the proven end.

Legal and regulatory status

The FDA (the US Food and Drug Administration) has not approved DSIP for any use. In the US, it’s sold as a “research chemical,” not as a medicine or a supplement. It had previously been treated as a Category 2 bulk substance — substances that raise meaningful safety concerns — for pharmacy compounding (mixing custom medications by hand). In an updated 503A document dated April 15, 2026, the FDA removed DSIP (listed as “Emideltide”) from Category 2 and lined it up for an advisory review. The Pharmacy Compounding Advisory Committee is set to discuss it — as “Emideltide (also referred to as delta sleep-inducing peptide (DSIP))” — on July 24, 2026, as part of a July 23-24 meeting, to weigh putting it on the 503A bulk drug substances list (Docket FDA-2025-N-6895). A scheduled review is not the same as approval, and none has been granted as of June 2026.

DSIP is not named on the WADA Prohibited List (WADA is the World Anti-Doping Agency, which sets the rules for banned substances in sports). Even so, unapproved peptides generally fall under category S0 (Non-Approved Substances) and are off-limits for athletes at all times. USADA (the US Anti-Doping Agency) has applied exactly this reasoning to other experimental peptides, such as BPC-157.

Safety

There’s no solid long-term or large-scale safety data in humans. The early trials reported few short-term side effects, but they were small and brief, so they can’t tell us much. And because DSIP is sold through unregulated channels, buyers also can’t be sure of its purity, dose, or whether it’s contaminated — problems that have led to failed drug tests and safety issues with peptides in general. None of this is medical advice.

Bottom line

DSIP is a real, naturally occurring peptide with only a handful of small, dated, and conflicting human sleep studies behind it. The signal is intriguing but unproven, and modern high-quality trials simply don’t exist. Evidence grade: 5/10 · Early.

Sources

• The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep — PubMed (PMID 7028502)
• Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia (Schneider-Helmert, European Neurology, 1987) — PubMed (PMID 3622582)
• A clinical trial with DSIP (Kaeser, European Neurology, 1984) — PubMed (PMID 6391926)
• Delta sleep-inducing peptide (DSIP): a still unresolved riddle (Kovalzon & Strekalova, 2006) — PubMed (PMID 16539679)
• Delta-sleep-inducing peptide — Wikipedia
• Pharmacy Compounding Advisory Committee; Notice of Meeting; Bulk Drug Substances Nominated for the 503A List — Federal Register (Docket FDA-2025-N-6895)
• July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee — FDA
• S0 Non-Approved Substances — WADA Prohibited List
• BPC-157: Experimental Peptide Creates Risk for Athletes — USADA